Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt

키워드

참고문헌 (33)

1. D’Amico G, "Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies", J Hepatol, 44, pp.217~231 (2006)
2. Weber CN, "Long-term patency and clinical analysis of expanded polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunt stent grafts", J Vasc Interv Radiol, 26, pp.1257~1265 (2015)
3. Tan HK, "Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion", J Gastroenterol Hepatol, 30, pp.389~395 (2015)
4. Bureau C, "Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites", Gastroenterology, 152, pp.157~163 (2017)
5. Ginés P, "Compensated cirrhosis : natural history and prognostic factors", Hepatology, 7, pp.122~128 (1987)
6. Pose E, "Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention", Dig Dis, 35, pp.402~410 (2017)
7. Grunwald D, "A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites", J Clin Gastroenterol, 50, pp.75~79 (2016)
8. Gaba RC, "Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation", J Vasc Interv Radiol, 24, pp.411~420 (2013)
9. Ahmed R, "MELD-Na as a prognostic indicator of 30-and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemi shunt", Eur J Gastroenterol Hepatol, 27, pp.1226~1227 (2015)
10. Chen RP, "Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites : metaregression and trial sequential meta-analysis", J Clin Gastroenterol, 48, pp.290~299 (2014)
11. Bureau C, "Serum bilirubin and platelet count : a simple predictive model for survival in patients with refractory ascites treated by TIPS", J Hepatol, 54, pp.901~907 (2011)
12. Rabie RN, "The use of E", A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt, 2009, pp.104, 2458~2466
13. Planas R, "Natural history of patients hospitalized for management of cirrhotic ascites", Clin Gastroenterol Hepatol, 4, pp.1385~1394 (2006)
14. Fasolato S, "Renal failure and bacterial infections in patients with cirrhosis : epidemiology and clinical features", Hepatology, 45, pp.223~229 (2007)
15. Kamath PS, "A model to predict survival in patients with endstage liver disease", Hepatology, 33, pp.464~470 (2001)
16. Moore KP, "The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club", Hepatology, 38, pp.258~266 (2003)
17. Casado M, "Clinical events after transjugular intrahepatic portosystemic shunt : correlation with hemodynamic findings", Gastroenterology, 114, pp.1296~1303 (1998)
18. Jiang Q, "Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt", World J Hepatol, 8, pp.850~857 (2016)
19. Hilden J, "Regret graphs, diagnostic uncertainty and Youden’s index", Stat Med, 15, pp.969~986 (1996)
20. DeLong GR, "Correlation of family history with specific autistic subgroups : Asperger’s syndrome and bipolar affective disease", J Autism Dev Disord, 18, pp.593~600 (1988)
21. Wong F, "Transjugular intrahepatic portosystemic stent shunt : effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites", Ann Intern Med, 122, pp.816~822 (1995)
22. D’Amico G, "Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites : a meta-analysis", Gastroenterology, 129, pp.1282~1293 (2005)
23. Chu CM, "Hepatitis B virus-related cirrhosis : natural history and treatment", Semin Liver Dis, 26, pp.142~152 (2006)
24. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
25. Ferral H, "Survival after elective transjugular intrahepatic portosystemic shunt creation : prediction with model for end-stage liver disease score", Radiology, 231, pp.231~236 (2004)
26. Lodato F, "Transjugular intrahepatic portosystemic shunt placement for refractory ascites : a single centre experience", Scand J Gastroenterol, 47, pp.1494~1500 (2012)
27. Post J, "Serum proteins in cirrhosis of the liver: I. Relation to prognosis and to formation of ascites", Arch Intern Med, 69, pp.67~82 (1942)
28. Mankin H, "Osmotic factors influencing the formation of ascites in patients with cirrhosis of the liver", J Clin Invest, 27, pp.145~153 (1948)
29. Witte MH, "Progress in liver disease : physiological factors involved in the causation of cirrhotic ascites", Gastroenterology, 61, pp.742~750 (1971)
30. Domenicali M, "Posttranscriptional changes of serum albumin : clinical and prognostic significance in hospitalized patients with cirrhosis", Hepatology, 60, pp.1851~1860 (2014)
31. Giannini E, "Platelet count", spleen diameter ratio : proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis, 2003, pp.52, 1200~1205
32. Schwarzenberger E, "Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis", J Clin Gastroenterol, 44, pp.146~150 (2010)
33. Berzigotti A, "Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis", Gastroenterology, 144, pp.102~111 (2013)

관련 논문AI추천